Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nanjing Shengde Biotech Co. Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit.
DUFFY, PATRICIA ANN is the busiest examiner, with 1 pending matter. Counsel can concentrate on the individual action, its claim issues, and the examination practices associated with the assigned biotechnology art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18993591 | L-HOMOSERINE HIGH-YIELD STRAIN, CONSTRUCTION METHOD THEREFOR, AND USE THEREOF | DUFFY, PATRICIA ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18993591 | L-HOMOSERINE HIGH-YIELD STRAIN, CONSTRUCTION METHOD THEREFOR, AND USE THEREOF | DUFFY, PATRICIA ANN | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18993591 | L-HOMOSERINE HIGH-YIELD STRAIN, CONSTRUCTION METHOD THEREFOR, AND USE THEREOF | DUFFY, PATRICIA ANN | 1645 | §103§112 | Non-Final OA | — | Pending | Jan 13, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanjing Shengde Biotech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Patricia Ann Duffy has the most, with 1 of Nanjing Shengde Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
